- Home
- UHG vs ELDN Comparison
UHG vs ELDN Comparison
Compare UHG & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- ELDN
- Stock Information
- Founded
- UHG 2004
- ELDN 2004
- Country
- UHG United States
- ELDN United States
- Employees
- UHG N/A
- ELDN N/A
- Industry
- UHG Homebuilding
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- UHG Consumer Discretionary
- ELDN Health Care
- Exchange
- UHG Nasdaq
- ELDN Nasdaq
- Market Cap
- UHG 242.0M
- ELDN 202.4M
- IPO Year
- UHG N/A
- ELDN N/A
- Fundamental
- Price
- UHG $3.98
- ELDN $2.72
- Analyst Decision
- UHG
- ELDN Strong Buy
- Analyst Count
- UHG 0
- ELDN 2
- Target Price
- UHG N/A
- ELDN $12.50
- AVG Volume (30 Days)
- UHG 216.5K
- ELDN 1.0M
- Earning Date
- UHG 08-07-2025
- ELDN 08-22-2025
- Dividend Yield
- UHG N/A
- ELDN N/A
- EPS Growth
- UHG N/A
- ELDN N/A
- EPS
- UHG 0.10
- ELDN N/A
- Revenue
- UHG $445,963,017.00
- ELDN N/A
- Revenue This Year
- UHG N/A
- ELDN N/A
- Revenue Next Year
- UHG N/A
- ELDN N/A
- P/E Ratio
- UHG $43.44
- ELDN N/A
- Revenue Growth
- UHG 7.51
- ELDN N/A
- 52 Week Low
- UHG $1.60
- ELDN $2.38
- 52 Week High
- UHG $6.93
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- UHG 53.84
- ELDN 37.28
- Support Level
- UHG $3.60
- ELDN $2.41
- Resistance Level
- UHG $4.49
- ELDN $3.51
- Average True Range (ATR)
- UHG 0.36
- ELDN 0.28
- MACD
- UHG -0.02
- ELDN -0.10
- Stochastic Oscillator
- UHG 42.70
- ELDN 19.81
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.